Prophylaxis of Primary Cytomegalovirus Disease in Renal Transplant Recipients

Abstract

These data suggest that prophylactic ganciclovir therapy provides a cost-effective approach toward significantly improving the outcome of renal transplantation in recipients at risk for primary CMV disease.